| 14 1 (7.69%) | 09-18 13:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.75 | 1-year : | 20.73 |
| Resists | First : | 15.19 | Second : | 17.75 |
| Pivot price | 12.6 |
|||
| Supports | First : | 9.82 | Second : | 6.5 |
| MAs | MA(5) : | 13.19 |
MA(20) : | 11.71 |
| MA(100) : | 8.75 |
MA(250) : | 6.77 |
|
| MACD | MACD : | 1.1 |
Signal : | 1 |
| %K %D | K(14,3) : | 71.8 |
D(3) : | 68 |
| RSI | RSI(14): 59 |
|||
| 52-week | High : | 15.19 | Low : | 0.47 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ZIVO ] has closed below upper band by 22.5%. Bollinger Bands are 127.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 23 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.51 - 13.56 | 13.56 - 13.62 |
| Low: | 12.86 - 12.92 | 12.92 - 12.98 |
| Close: | 13.39 - 13.49 | 13.49 - 13.59 |
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Bloomfield Hills, Michigan.
Fri, 30 Aug 2024
ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Crosses Above 50 Day Moving Average of $8.36 - Defense World
Fri, 23 Aug 2024
Director and 10% Owner Christopher Maggiore Acquires 31,336 Shares of Zivo Bioscience Inc (ZIVO) - Yahoo Finance
Thu, 15 Aug 2024
Marquis Who's Who Honors Nola E. Masterson for Expertise in Investing - 24-7 Press Release
Mon, 18 Mar 2024
SMCI Stock Alert: Super Micro Computer Joins the S&P 500 Today - InvestorPlace
Fri, 30 Jun 2023
ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market - StockTitan
Mon, 20 Sep 2021
ZIVO Stock: 8 Things to Know About Biotech Play Zivo Bioscience as Shares Rocket 155%+ - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.37e+006 (%) |
| Held by Institutions | 1.77e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.33 |
| Profit Margin | 0 % |
| Operating Margin | -21 % |
| Return on Assets (ttm) | 871.9 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -2.63 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 35470 |
| Forward Dividend | 12810 |
| Dividend Yield | 253357% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|